TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01730027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC3680
Description: ADC3680 for 12 weeks plus montelukast for the last 2 weeks of the dosing period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks plus montelukast for the last 2 weeks of the dosing period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: montelukast for 12 weeks
Study: NCT01335048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin and clopidogrel
Description: Atorvastatin 80 mg daily + clopidogrel 150 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 150 mg daily
Study: NCT03619239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.
Study: NCT02932527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire about cannabis consumption
Description: Questionnaire about cannabis consumption will be assessed to infertile male exposed to cannabis and infertile male not exposed to cannabis.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire about cannabis consumption
Description: Questionnaire about cannabis consumption will be assessed to infertile male exposed to cannabis and infertile male not exposed to cannabis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood intake
Description: blood intake is done for infertile male exposed and infertile male not exposed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood intake
Description: blood intake is done for infertile male exposed and infertile male not exposed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Semen samples collection
Description: Semen samples are collected for infertile male exposed and infertile male not exposed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Semen samples collection
Description: Semen samples are collected for infertile male exposed and infertile male not exposed.
Study: NCT04428476

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Deramiocel (CAP-1002)
Description: Peripheral infusion of 150 million allogeneic cardiosphere-derived cells administered every three months
Study: NCT01490073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of nitroglycerin ointment
Description: Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insertion of placebo ointment
Description: Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion
Study: NCT02235077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.~Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.~Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding.
Study: NCT01682226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Fractionation system (Arm A)
Description: 7 days before transplant Admit to hospital. Line insertion 6 days before transplant Fludarabine (chemotherapy) Cyclophosphamide (chemotherapy) 5 days before transplant Fludarabine Thiotepa 4 days before transplant Fludarabine Thiotepa 3 days before transplant Fludarabine Start CSA and MMF 2 days before transplant Fludarabine and TBI (radiation therapy)~1 day before transplant TBI (radiation therapy) Day of transplant Transplant day (infuse cord blood) Day after cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Fractionation system (Arm B)
Description: 8 days before transplant Admit to hospital. Line insertion 7 days before transplant Fludarabine 6 days before transplant Fludarabine Cyclophosphamide 5 days before transplant Fludarabine Cyclophosphamide 4 days before transplant Rest 3 days before transplant TBI x 3 Start CSA and MMF 2 days before transplant TBI x 3~1 day before transplant TBI x 3 Day of transplant TBI x 2 then infuse cord blood~1 day after the cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical donor CD34+ cells
Description: CB grafts will consist of two CB units 4-6/6 HLA-matched to the patient to augment graft cell dose and additional T-cell depleted PBSC from a haplo-identical donor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical donor CD34+ cells
Description: CB grafts will consist of two CB units 4-6/6 HLA-matched to the patient to augment graft cell dose and additional T-cell depleted PBSC from a haplo-identical donor.
Study: NCT02036840

Intervention type: DRUG
Intervention: Antibiotic
Study: NCT05364281

Intervention type: OTHER
Intervention: Intracuff pressure measurement
Description: The intracuff pressures were measured and noted after each position (neck extension and placement of mouth gag), at every 5th minute while the operation and before the extubating.
Study: NCT04333095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Sternal Block during Coronary Artery Bypass Graft Surgery and/or surgical aortic valve replacement through mini- or full sternotomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution_#1
Description: Sternal Block during Coronary Artery Bypass Graft Surgery and/or surgical aortic valve replacement through mini- or full sternotomy
Study: NCT00930774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FM system
Description: Frequency modulation assistive device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FM system
Description: Frequency modulation assistive device

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory training
Description: Participation in computerized auditory training program for eight weeks
Study: NCT00377286

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 16 oz lite lemonade
Description: 16 oz lite lemonade 1 time daily for 6 months
Study: NCT02468635

Intervention type: OTHER
Group type: OTHER
Intervention: upper limb exercises
Description: HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESISTANCE STAGE: upper limb exercises with weight training equipment or dumbbells (the patient's adaptation) with 50% of maximum load reached the maximum repetition test. Series 2 minutes and rest interval between sets 1-2 minutes. RESPIRATORY TRAINING : Strengthening of the respiratory muscles 5-15 minutes with Threshold with load of 50% of the affected MIP (measure maximal inspiratory pressure) evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
Study: NCT00930774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory training
Description: Participation in computerized auditory training program for eight weeks
Study: NCT04176315

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Home-based Rehabilitation Plan
Description: Usual intervention at Presidio Sanitario San Camillo for post-operative rehabilitation of THA patients. Participants receive inpatient care and rehabilitation for 2 weeks. At discharge, they receive a 5-exercise home-based rehabilitation plan. For the sake of homogeneity of all participants, they receive from 2 to 4 of training prior to discharge. At home, participants shall perform the exercises in the rehabilitation plan daily.
Study: NCT02468635

Intervention type: OTHER
Group type: OTHER
Intervention: without training for upper limb
Description: HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESPIRATORY TRAINING: Strengthening respiratory muscles 5-15 minutes with Threshold with load of 50% of MIP hit in the evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
Study: NCT03621202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saranas Early Bird Bleed Monitoring System (EBBMS)
Description: Participants will undergo their planned endovascular procedure with monitoring for internal bleeding using the Saranas EBBMS.
Study: NCT04129814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy
Description: single session full-mouth scaling and root planing
Study: NCT01406522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral tacrine
Description: Tacrine, 160 mg per day, four times daily
Study: NCT04176315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReHub Home-based Rehabilitation Plan
Description: Combination of the usual intervention at Presidio Sanitario San Camillo for post-operative rehabilitation of THA patients with ReHub, a telerehabilitation platform that serves as a guide to perform the TKA rehabilitation exercises.~Participants receive inpatient care and rehabilitation at San Camillo for 2 weeks. At discharge, a 5-exercise home-based rehabilitation plan is carried out by a site physiotherapist by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor. Participants receive from 2 to 4 sessions of ReHub prior to discharge.~At home, participants shall perform the exercises in the rehabilitation plan with ReHub daily. The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. Participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely.
Study: NCT01406522

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Description: Microcrystalline cellulose
Study: NCT04369001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-Based Exercise
Description: Participants will complete 150 minutes of exercise per week for 12 weeks. Exercise per week will be documented using exercise logs. The exercise protocol will be a culturally-tailored community-based exercise intervention based on the aerobic exercise goals used in the Program ACTIVE study and psychoeducational materials adapted from Program ACTIVE based on feedback from Black men with T2D. Exercise in Program ACTIVE will be obtained through individualized community-based activities that participants in the focus groups indicate as feasible rather than the highly controlled laboratory environment. Exercise goals will be adapted to accommodate the physical and medical restrictions of an older-adult diabetes population.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants will receive 10 sessions of CBT using a manualized approach based on Beck's model of cognitive therapy. Sessions are to be completed once weekly in conjunction with weekly exercise. The Program ACTIVE CBT intervention includes: presentation of CBT model; thought records, cognitive distortions, counterarguments, cognitive reframing, automatic thoughts, core beliefs, and relapse prevention. Session goals will be tailored to the needs of men so that the order of topics may vary. Each session will begin with the designation of session goals, review of previously assigned homework, and introduction of new concepts and skills. Individually-tailored homework assignments designed to provide practice with the concepts/skills of the session will be assigned.
Study: NCT00743561

Intervention type: DEVICE
Group type: OTHER
Intervention: Polysomnography
Description: Simultaneous recording of electro-encephalography, tibial and submental electro-myography, electro-oculography, nasal air flow, oxygen saturation, as well as the thoracic and abdominal respiratory effort

Intervention type: DEVICE
Group type: OTHER
Intervention: ambulatory polygraphy
Description: Simultaneous recording of nasal air flow, oxygen saturation, as well as the abdominal and thoracic respiratory effort.
Study: NCT04416698

Intervention type: BEHAVIORAL
Intervention: Individual qualitative interview
Description: Individual interviews will be conducted to understanding the needs and concerns of youth smokers of e-cigarette or other new tobacco products, including their risk perceptions, and the behaviour, attitudes, and experiences related to these tobacco products.

Intervention type: BEHAVIORAL
Intervention: cross-sectional survey study
Description: structured questionnaire will be constructed for a cross-sectional survey to further explore the behaviour, attitudes, and experiences related to electronic cigarettes or other new tobacco products among youth.
Study: NCT03507322

Intervention type: OTHER
Intervention: Ultrasound texturization
Description: Along several visits to the clinic, the patients will be subjected to 2D/3D ultrasound scanning.
Study: NCT03391570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COX-2 inhibitor
Description: Celebrex 200mg/1cap 2 tablets, take medication an hour before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Ramnos 250mg/1cap 2 tablets, take medication an hour before surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative peritoneal biopsy
Description: Preoperative peritoneal biopsy (1x1cm sized peritoneal tissue)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Preoperative peritoneal biopsy
Description: Preoperative peritoneal biopsy (1x1cm sized peritoneal tissue)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-port laparoscopic surgery
Description: Single-port laparoscopic surgery with CO2 gas

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Single-port laparoscopic surgery
Description: Single-port laparoscopic surgery with CO2 gas

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative peritoneal biopsy
Description: Postoperative peritoneal biopsy (1x1cm sized peritoneal tissue)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative peritoneal biopsy
Description: Postoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
Study: NCT00886639

Intervention type: OTHER
Group type: OTHER
Intervention: 6MWT with oxygen
Description: 2 liter per minute as continuous-flow

Intervention type: OTHER
Group type: OTHER
Intervention: 6MWT with oxygen
Description: 2 liter per minute as continuous-flow

Intervention type: OTHER
Group type: OTHER
Intervention: 6MWT with medical air
Description: 2 liters as continuous-flow

Intervention type: OTHER
Group type: OTHER
Intervention: 6MWT with medical air
Description: 2 liters as continuous-flow
Study: NCT01058317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 2mg/kg divided twice daily
Study: NCT01928134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit K2+ Vit D3+ calcium carbonate (CaCO3)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vit K2+CaCO3
Study: NCT02168764

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATI Neurostimulation System
Description: All subjects will be implanted with the ATI Neurostimulator which, along with the ATI Remote Controller, provides electrical stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATI Neurostimulation System
Description: All subjects will be implanted with the ATI Neurostimulator which, along with the ATI Remote Controller, provides electrical stimulation.
Study: NCT00051168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travatan
Description: Travoprost (0.004%) 1 drop each eye once daily
Study: NCT03243162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBPT-ACLR
Description: The CBPT-ACLR program focuses on improving sports function and return to sport. CBPT-ACLR sessions cover realistic expectations, relaxation strategies, problem-solving training, cognitive restructuring, and behavioral self-management (i.e., graded activity, goal setting, managing setbacks and symptom management plans). Each session builds upon the content of the previous session using an action plan and weekly homework is personally tailored based on patient goals. The program consists of one preoperative telephone session and six postoperative telephone sessions with a physical therapist. Each patient randomized into the CBPT-ACLR program will receive a manual to follow along with the study therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The education program focuses on postoperative ACLR recovery. Sessions address benefits of physical therapy, proper biomechanics during sports and other functional activity, importance of early exercise after surgery, and ways to promote healing. Education on stress reduction, sleep hygiene, energy management, communication with health providers, and preventing future injury are also provided. The Education program is matched to the CBPT-ACLR treatment in terms of session frequency, length and contact with the study therapist. Each patient randomized into the Education program will receive a manual to follow along with the study therapist.
Study: NCT05166525

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medically tailored meals
Description: Compare medically tailored meals vs. medically tailored meals with enhanced nutritional counseling vs. usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medically tailored meals
Description: Compare medically tailored meals vs. medically tailored meals with enhanced nutritional counseling vs. usual care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medically tailored meals
Description: Compare medically tailored meals vs. medically tailored meals with enhanced nutritional counseling vs. usual care
Study: NCT04036461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99712
Description: CC-99712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99712
Description: CC-99712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986405
Description: BMS-986405
Study: NCT01736059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD34+ bone marrow stem cells intravitreal
Study: NCT04429087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764532 - parenteral 1
Description: BI 764532 - parenteral 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764532 - parenteral 2
Description: BI 764532 - parenteral 2
Study: NCT00256503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia
Description: Insomnia Subjects receive CBT-I
Study: NCT03340948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: An 8-week course in mindfulness meditation, yoga training and weekly group support in the form of weekly 2,5 hour meetings at the hospital.
Study: NCT03315130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zilucoplan (RA101495)
Description: Daily subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zilucoplan (RA101495)
Description: Daily subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous (SC) injection
Study: NCT03079310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Range of pulse widths (200-500 microseconds) and frequencies (30-130 Hz) will be assessed for each patient
Study: NCT03977233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: 180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle
Study: NCT03887780

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto,Bay 59-7939)
Description: 15 mg and 20 mg (OD)
Study: NCT03537014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Non-directive therapy performed by therapist team

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Non-directive therapy performed by therapist team

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midomafetamine HCl
Description: Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental dose 1.5 to 2 hrs later of 40 or 60 mg midomafetamine HCl, respectively, during three experimental sessions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo during three experimental sessions